|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DRAP1 |
Gene summary for DRAP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DRAP1 | Gene ID | 10589 |
| Gene name | DR1 associated protein 1 | |
| Gene Alias | NC2-alpha | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q14919 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10589 | DRAP1 | Dong_P1 | Human | Prostate | Tumor | 6.14e-34 | 1.22e-01 | 0.035 |
| 10589 | DRAP1 | Dong_P3 | Human | Prostate | Tumor | 2.56e-21 | -9.96e-02 | 0.0278 |
| 10589 | DRAP1 | Dong_P4 | Human | Prostate | Tumor | 7.80e-10 | -1.04e-01 | 0.0292 |
| 10589 | DRAP1 | Dong_P5 | Human | Prostate | Tumor | 2.34e-27 | 1.33e-01 | 0.053 |
| 10589 | DRAP1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 4.30e-02 | -5.36e-01 | 0.1633 |
| 10589 | DRAP1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 5.16e-12 | -7.18e-01 | 0.1608 |
| 10589 | DRAP1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 2.04e-06 | -7.17e-01 | 0.1604 |
| 10589 | DRAP1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.89e-02 | -5.74e-01 | 0.1621 |
| 10589 | DRAP1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 3.49e-09 | -7.16e-01 | 0.1602 |
| 10589 | DRAP1 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 7.60e-07 | -5.54e-01 | 0.1575 |
| 10589 | DRAP1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.21e-18 | -6.67e-01 | 0.1545 |
| 10589 | DRAP1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.86e-10 | -6.76e-01 | 0.1569 |
| 10589 | DRAP1 | P2_S3_AK | Human | Skin | AK | 1.81e-05 | -1.75e-01 | -0.3287 |
| 10589 | DRAP1 | P3_S6_AK | Human | Skin | AK | 8.13e-06 | -4.08e-01 | -0.3256 |
| 10589 | DRAP1 | P4_S8_cSCC | Human | Skin | cSCC | 1.68e-06 | 1.50e-01 | -0.3095 |
| 10589 | DRAP1 | P5_S10_cSCC | Human | Skin | cSCC | 6.74e-12 | 1.20e-02 | -0.299 |
| 10589 | DRAP1 | P1_cSCC | Human | Skin | cSCC | 9.20e-34 | 1.35e+00 | 0.0292 |
| 10589 | DRAP1 | P2_cSCC | Human | Skin | cSCC | 4.25e-23 | 9.87e-01 | -0.024 |
| 10589 | DRAP1 | P4_cSCC | Human | Skin | cSCC | 1.66e-45 | 1.67e+00 | -0.00290000000000005 |
| 10589 | DRAP1 | P10_cSCC | Human | Skin | cSCC | 5.35e-38 | 1.69e+00 | 0.1017 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DRAP1 | SNV | Missense_Mutation | c.239T>A | p.Phe80Tyr | p.F80Y | Q14919 | protein_coding | deleterious(0.01) | possibly_damaging(0.804) | TCGA-OL-A66N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| DRAP1 | SNV | Missense_Mutation | c.326N>A | p.Arg109His | p.R109H | Q14919 | protein_coding | tolerated(0.11) | benign(0.027) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DRAP1 | SNV | Missense_Mutation | novel | c.8N>T | p.Ser3Ile | p.S3I | Q14919 | protein_coding | deleterious(0.03) | possibly_damaging(0.497) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| DRAP1 | SNV | Missense_Mutation | c.179N>A | p.Arg60Gln | p.R60Q | Q14919 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| DRAP1 | SNV | Missense_Mutation | rs781734189 | c.598G>A | p.Glu200Lys | p.E200K | Q14919 | protein_coding | deleterious_low_confidence(0.01) | benign(0.269) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DRAP1 | SNV | Missense_Mutation | rs143922438 | c.580G>A | p.Ala194Thr | p.A194T | Q14919 | protein_coding | tolerated_low_confidence(0.15) | benign(0.11) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DRAP1 | insertion | Frame_Shift_Ins | rs751570365 | c.513-1_513insC | p.Thr174AspfsTer23 | p.T174Dfs*23 | Q14919 | protein_coding | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| DRAP1 | SNV | Missense_Mutation | c.266C>A | p.Ser89Tyr | p.S89Y | Q14919 | protein_coding | deleterious(0) | possibly_damaging(0.79) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| DRAP1 | SNV | Missense_Mutation | rs777331540 | c.538G>A | p.Ala180Thr | p.A180T | Q14919 | protein_coding | tolerated_low_confidence(0.65) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| DRAP1 | SNV | Missense_Mutation | rs777331540 | c.538G>A | p.Ala180Thr | p.A180T | Q14919 | protein_coding | tolerated_low_confidence(0.65) | benign(0) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |